The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A phase 1, dose-finding and expansion study (NCT04214860) was conducted to evaluate combined therapy using APR-246 and venetoclax with or without AZA in AML patients with p53 mutation.336 No dose-limiting toxicities (DLTs) were observed, and the recommended phase 2 dose for the APR-246 combination was 4.5 g/day on days 1–4.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [336]
In the citing paper
“The overall response rate for APR-246 and venetoclax with AZA was 64% (25/39), and the complete response rate (CRR) was 38% (15/39).”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [336]
In the citing paper
“More than 20% of patients experienced ≥grade 3 adverse events (AEs), including febrile neutropenia (47%, 23/49), thrombocytopenia (37%, 18/49), leukopenia (25%, 12/49), and anemia (22%, 11/49).”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [336]
In the citing paper
“These results suggest that the combination of APR-246 and venetoclax with AZA has surprising activity and acceptable safety.336”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [336]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
Self-citationAPR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Birsen, R., Larrue, C., Decroocq, J., Johnson, N., Guiraud, N., Gotanegre, M., Cantero-Aguilar, L., Grignano, E., Huynh, T., Fontenay, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.259531 · Cited by 182
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161
Self-citationPollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., Dail, M., Sun, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1183 · Cited by 159
Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133
Self-citationMaslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132
Research works printed but not linked: 19
- Kadia, 2016, TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes, Cancer, 122, 3484, 10.1002/cncr.30203 · DOI · Paper page
- Sallman, 2016, Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes, Leukemia, 30, 666, 10.1038/leu.2015.304 · DOI · Paper page
- Short, 2020, Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia, Blood Adv, 4, 5681, 10.1182/bloodadvances.2020003120 · DOI · Paper page
- Grob, 2022, Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome, Blood, 139, 2347, 10.1182/blood.2021014472 · DOI · Paper page
- Bowen, 2009, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, 23, 203, 10.1038/leu.2008.173 · DOI · Paper page
- Strickland, 2018, Cytogenetic and molecular drivers of outcome with venetoclax-based combination therapies in treatment-naive elderly patients with acute myeloid leukaemia (AML), Clin Lymphoma Myeloma Leuk, 8, S202, 10.1016/j.clml.2018.07.052 · doi:10.1016/j.clml.2018.07.052
- DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 · DOI · Paper page
- Aldoss, 2019, Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia, Br J Haematol, 187, e45, 10.1111/bjh.16166 · DOI
- DiNardo, 2020, Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML, Blood, 135, 791, 10.1182/blood.2019003988 · DOI · Paper page
- DiNardo, 2019, Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood, 133, 7, 10.1182/blood-2018-08-868752 · DOI · Paper page
- Zhang, 2018, APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis, 9, 439, 10.1038/s41419-018-0463-7 · DOI · Paper page
- Bykov, 2016, Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy, Front Oncol, 6, 21, 10.3389/fonc.2016.00021 · DOI · Paper page
- Cluzeau, 2021, Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM), J Clin Oncol, 39, 1575, 10.1200/JCO.20.02342 · DOI · Paper page
- Sallman, 2021, Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML), Blood, 138, 246, 10.1182/blood-2021-153286 · DOI
- Cheson, 2003, Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia, J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 · DOI · Paper page
- Pollyea, 2022, Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine, Clin Cancer Res, 28, 5272, 10.1158/1078-0432.CCR-22-1183 · DOI · Paper page
- Mishra, 2022, Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes, J Clin Oncol, 40, 3985, 10.1200/JCO.22.00181 · DOI · Paper page
- Daver, 2022, Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results, J Clin Oncol, 40, 10.1200/JCO.2022.40.16_suppl.7020 · DOI
- Brunner, 2021, Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study, Blood, 138, 244, 10.1182/blood-2021-146039 · DOI
Cited by
Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Garcia-Manero, G., Goldberg, A. D., Winer, E. S., Altman, J. K., Fathi, A. T., Odenike, O., Roboz, G. J., Sweet, K., Miller, C., Wennborg, A., Hickman, D. K., Kanagal-Shamanna, R., Kantarjian, H., Lancet, J., Komrokji, R., Attar, E. C., & Sallman, D. A.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 10
- Issue
- 4
- Pages
- e272-e283
- ISSN
- 2352-3026
- Cited by
- 88
- References
- 13
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. https://app.cochat.ai/papers/10.1016/s2352-3026(22)00403-3
- The paper
- Garcia-Manero, G., Goldberg, A. D., Winer, E. S., Altman, J. K., Fathi, A. T., Odenike, O., Roboz, G. J., Sweet, K., Miller, C., Wennborg, A., Hickman, D. K., Kanagal-Shamanna, R., Kantarjian, H., Lancet, J., Komrokji, R., Attar, E. C., & Sallman, D. A. (2023). Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00403-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
